Nothing Special   »   [go: up one dir, main page]

EP0879279A4 - Diabetes therapy - Google Patents

Diabetes therapy

Info

Publication number
EP0879279A4
EP0879279A4 EP97905834A EP97905834A EP0879279A4 EP 0879279 A4 EP0879279 A4 EP 0879279A4 EP 97905834 A EP97905834 A EP 97905834A EP 97905834 A EP97905834 A EP 97905834A EP 0879279 A4 EP0879279 A4 EP 0879279A4
Authority
EP
European Patent Office
Prior art keywords
diabetes therapy
diabetes
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97905834A
Other languages
German (de)
French (fr)
Other versions
EP0879279A1 (en
Inventor
Tracy L Borts
Carol L Broderick
Richard D Dimarchi
Brian W Grinnell
Anne R Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603847.6A external-priority patent/GB9603847D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of EP0879279A1 publication Critical patent/EP0879279A1/en
Publication of EP0879279A4 publication Critical patent/EP0879279A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP97905834A 1996-02-06 1997-02-06 Diabetes therapy Withdrawn EP0879279A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US1211196P 1996-02-06 1996-02-06
US12111P 1996-02-06
GBGB9603847.6A GB9603847D0 (en) 1996-02-23 1996-02-23 Diabetes therapy
GB9603847 1996-02-23
PCT/US1997/001978 WO1997029180A1 (en) 1996-02-06 1997-02-06 Diabetes therapy

Publications (2)

Publication Number Publication Date
EP0879279A1 EP0879279A1 (en) 1998-11-25
EP0879279A4 true EP0879279A4 (en) 2000-07-12

Family

ID=26308793

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97905834A Withdrawn EP0879279A4 (en) 1996-02-06 1997-02-06 Diabetes therapy

Country Status (5)

Country Link
EP (1) EP0879279A4 (en)
JP (1) JP2001503963A (en)
AU (1) AU2263197A (en)
CA (1) CA2243718A1 (en)
WO (1) WO1997029180A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
WO1997038293A2 (en) 1996-04-11 1997-10-16 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
JP2002510193A (en) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー Glucagon-like peptide-1 analog
AU6586298A (en) * 1997-03-31 1998-10-22 Eli Lilly And Company Glucagon-like peptide-1 analogs
AU3047299A (en) * 1998-04-13 1999-11-01 Modex Therapeutiques, S.A. Methods of delivering glp-1
KR20050037004A (en) 1998-12-07 2005-04-20 소시에떼 더 콘세이유 더 레세르세 에 다플리까띠옹 시엔띠피끄, 에스.아.에스. Analogues of glp-1
AU770609B2 (en) * 1998-12-07 2004-02-26 Ipsen Pharma S.A.S. GLP-1 analogues
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2000062862A1 (en) * 1999-04-15 2000-10-26 South Eastern Sydney Area Health Service Method of prophylaxis and treatment of diabetes
WO2001035988A1 (en) * 1999-11-12 2001-05-25 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
EP1234038A1 (en) 1999-11-19 2002-08-28 Transkaryotic Therapies, Inc. Nucleic acid construct for optimized production of products
US20020025306A1 (en) * 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
CN1363654A (en) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 Genetically engineered bacteria and process for preparing insulinotropic hormone secretion peptide GLP-1 (7-36)
JP2007536214A (en) 2003-12-16 2007-12-13 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス GLP-1 analog
WO2005058252A2 (en) 2003-12-16 2005-06-30 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Glp-1 pharmaceutical compositions
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
EP2570133B1 (en) 2005-11-07 2016-03-23 Indiana University Research and Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
ES2628063T3 (en) 2007-01-05 2017-08-01 Indiana University Research And Technology Corporation Glucagon analogs showing greater solubility in physiological pH buffers
CA2677932A1 (en) 2007-02-15 2008-08-21 Indiana University Research And Technology Corporation Glucagon/glp-1 receptor co-agonists
AU2008318876B2 (en) 2007-10-30 2014-05-15 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and GLP-1 agonist activity
EP2217701B9 (en) 2007-10-30 2015-02-18 Indiana University Research and Technology Corporation Glucagon antagonists
CA2758023A1 (en) 2008-04-09 2009-10-15 Cornell University Commensal bacteria as signal mediators within a mammalian host
CA2727161A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
JP6108659B2 (en) 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ GIP-based mixed agonist for the treatment of metabolic diseases and obesity
EP2676673B1 (en) 2008-06-17 2016-11-16 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
EP2376097A4 (en) 2008-12-19 2012-10-03 Univ Indiana Res & Tech Corp Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
IN2012DN06437A (en) 2010-01-27 2015-10-09 Univ Indiana Res & Tech Corp
KR20130062931A (en) 2010-05-13 2013-06-13 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting nuclear hormone receptor activity
WO2011143208A1 (en) 2010-05-13 2011-11-17 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
KR20130102470A (en) 2010-06-24 2013-09-17 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Amide based glucagon superfamily peptide prodrugs
CA2814698A1 (en) 2010-10-15 2012-04-19 Cornell University Compositions and methods for treating endocrine, gastrointestinal or autoimmune disorders
ES2713952T3 (en) 2010-12-22 2019-05-24 Univ Indiana Res & Tech Corp Glucagon analogs showing GIP receptor activity
KR20140043793A (en) 2011-06-22 2014-04-10 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon/glp-1 receptor co-agonists
US9156902B2 (en) 2011-06-22 2015-10-13 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
JP6324315B2 (en) 2011-11-17 2018-05-16 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon superfamily of peptides exhibiting glucocorticoid receptor activity
CN104583232B (en) 2012-06-21 2018-04-13 印第安纳大学研究及科技有限公司 Show the glucagon analogs of GIP receptor actives
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499990A2 (en) * 1991-02-19 1992-08-26 Takeda Chemical Industries, Ltd. Method for producing cysteine-free peptides
WO1993009222A2 (en) * 1991-11-05 1993-05-13 Transkaryotic Therapies, Inc. Transfection of vertebrate cells e.g. by homologous recombination
EP0619322A2 (en) * 1993-04-07 1994-10-12 Pfizer Inc. Prolonged delivery of peptides
WO1995003405A2 (en) * 1993-07-20 1995-02-02 Bionebraska, Inc. Enzymatic method for modification of recombinant polypeptides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
GB9502830D0 (en) * 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0499990A2 (en) * 1991-02-19 1992-08-26 Takeda Chemical Industries, Ltd. Method for producing cysteine-free peptides
WO1993009222A2 (en) * 1991-11-05 1993-05-13 Transkaryotic Therapies, Inc. Transfection of vertebrate cells e.g. by homologous recombination
EP0619322A2 (en) * 1993-04-07 1994-10-12 Pfizer Inc. Prolonged delivery of peptides
WO1995003405A2 (en) * 1993-07-20 1995-02-02 Bionebraska, Inc. Enzymatic method for modification of recombinant polypeptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9729180A1 *

Also Published As

Publication number Publication date
WO1997029180A1 (en) 1997-08-14
EP0879279A1 (en) 1998-11-25
AU2263197A (en) 1997-08-28
CA2243718A1 (en) 1997-08-14
JP2001503963A (en) 2001-03-27

Similar Documents

Publication Publication Date Title
EP0879279A4 (en) Diabetes therapy
EG24678A (en) Combination therapy
PL331901A1 (en) Syringe
PL331209A1 (en) Syringe
AP2002002661A0 (en) Combination therapy for oesteoporosis
ZA982368B (en) New therapeutic combinations
IL127306A0 (en) Combination therapy
ZA9533B (en) Pentolifylline therapy
GB9700899D0 (en) Novel treatment
ZA973209B (en) Therapeutic compounds.
GB9700939D0 (en) Therapy
GB9600143D0 (en) Therapeutic compounds
GB9606076D0 (en) Diabetes treatment
GB9620777D0 (en) Therapeutic use
GB9901108D0 (en) Anti-reuse syringe
HUP0000089A3 (en) Syringe
ZA9711533B (en) Therapeutic compounds
ZA977005B (en) Therapeutic uses
GB9603847D0 (en) Diabetes therapy
GB2304046B (en) Diabetes therapy
GB9617550D0 (en) Medical ice-pack
GB9721692D0 (en) Novel treatment
GB9605466D0 (en) Therapy
GB9605525D0 (en) Therapy
GB9410971D0 (en) Diabetes treatment

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980727

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

AX Request for extension of the european patent

Free format text: RO PAYMENT 980727

A4 Supplementary search report drawn up and despatched

Effective date: 20000526

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20020913

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030124

R18D Application deemed to be withdrawn (corrected)

Effective date: 20030325